Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma.
作者信息
Liu Jing, Liao Xuanzhi, Gu Yingying, Fu Lin, Zhao Jin, Li Longguang, Chen Zhucheng, Jiang Juhong
机构信息
The State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, China.
出版信息
J Thorac Dis. 2018 Sep;10(9):5522-5530. doi: 10.21037/jtd.2018.08.59.
Abstract
摘要
相似文献
1
Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma.p16缺失和BAP1缺失在恶性间皮瘤诊断中的作用。
J Thorac Dis. 2018 Sep;10(9):5522-5530. doi: 10.21037/jtd.2018.08.59.
2
Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.检测 BAP1 缺失和 CDKN2A/p16 纯合性缺失可提高浆膜腔细胞学中间皮增生的准确诊断。
Cancer Cytopathol. 2020 Dec;128(12):939-947. doi: 10.1002/cncy.22326. Epub 2020 Jul 17.
3
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.BAP1免疫组化和p16（CDKN2A）荧光原位杂交技术在胸腔积液细胞学标本恶性间皮瘤诊断中的应用价值
Am J Surg Pathol. 2016 Jan;40(1):120-6. doi: 10.1097/PAS.0000000000000529.
4
Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.胸腔细胞学标本中 MTAP 和 BAP1 染色丢失及 P16/CDKN2A 缺失的研究及其在间皮瘤诊断中的作用。
Diagn Cytopathol. 2024 Apr;52(4):211-216. doi: 10.1002/dc.25272. Epub 2024 Jan 20.
5
Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.胸腔积液细胞学中 BAP1 缺失和 p16（CDKN2A）缺失分析对间皮瘤明确诊断的贡献。
Eur Rev Med Pharmacol Sci. 2023 Oct;27(20):10001-10007. doi: 10.26355/eurrev_202310_34180.
6
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.作为恶性胸膜间皮瘤中CDKN2A（p16）荧光原位杂交的补充，BAP1免疫组化的预后效用有限。
Hum Pathol. 2017 Feb;60:86-94. doi: 10.1016/j.humpath.2016.09.026. Epub 2016 Oct 19.
7
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.BAP1免疫组化和p16荧光原位杂交结果联合使用可提高恶性胸膜间皮瘤诊断的可信度：两种检测方法的ROC分析
Pathol Int. 2016 Oct;66(10):563-570. doi: 10.1111/pin.12453. Epub 2016 Sep 11.
8
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.免疫组化检测 MTAP 和 BAP1 蛋白缺失在间皮瘤诊断中的应用：与 9p21 FISH 和 BAP1 免疫组化的比较。
Lung Cancer. 2017 Feb;104:98-105. doi: 10.1016/j.lungcan.2016.12.017. Epub 2016 Dec 23.
9
Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.肉瘤样间皮瘤：53 例免疫组织化学相关性 CDKN2A 分子分析与 BAP1 的关系。
Pathol Res Pract. 2020 Dec;216(12):153267. doi: 10.1016/j.prp.2020.153267. Epub 2020 Nov 2.
10
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.双相性间皮瘤诊断可重复性的新见解：来自 MESOPATH 参考中心的国际间皮瘤专家组的多机构评估。
J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30.
引用本文的文献
1
Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues.一名患有进展迅速的肉瘤样胸膜间皮瘤的患者的详细临床过程，该患者无 p16 缺失，伴有全身血源性软组织转移。
BMJ Case Rep. 2024 Feb 10;17(2):e257618. doi: 10.1136/bcr-2023-257618.
2
Deletions of and Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma.通过拷贝数变异阵列检测到的 和 的缺失与胸膜间皮瘤中p16和MTAP蛋白的缺失相关。
Cancers (Basel). 2023 Oct 13;15(20):4978. doi: 10.3390/cancers15204978.
3
Synchronous Jejunal Sarcomatoid Carcinoma and Incidentally Associated Localized Peritoneal Malignant Mesothelioma.同步性空肠肉瘤样癌及偶然发现的局部腹膜恶性间皮瘤
Cureus. 2022 Jun 24;14(6):e26270. doi: 10.7759/cureus.26270. eCollection 2022 Jun.
4
Pediatric Peritoneal Epithelial Malignant Mesothelioma Case Report.小儿腹膜上皮性恶性间皮瘤病例报告
Case Rep Radiol. 2021 Nov 9;2021:5581757. doi: 10.1155/2021/5581757. eCollection 2021.
5
The Use of Immunohistochemistry, Fluorescence Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review.免疫组织化学、荧光杂交及新兴表观遗传标志物在恶性胸膜间皮瘤（MPM）诊断中的应用：综述
Front Oncol. 2020 Sep 9;10:1742. doi: 10.3389/fonc.2020.01742. eCollection 2020.
6
A challenging diagnosis of malignant mesothelioma with osteosarcomatous differentiation metastasizing to bone.一例具有骨肉瘤样分化并转移至骨的恶性间皮瘤的疑难诊断。
Respirol Case Rep. 2020 Sep 19;8(8):e00664. doi: 10.1002/rcr2.664. eCollection 2020 Nov.
本文引用的文献
1
Improving the Accuracy of Mesothelioma Diagnosis in China.提高中国间皮瘤诊断的准确性。
J Thorac Oncol. 2017 Apr;12(4):714-723. doi: 10.1016/j.jtho.2016.12.006. Epub 2016 Dec 19.
2
Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs.肺腺癌患者中p16/CDKN2A纯合缺失与表皮生长因子受体（EGFR）激活突变共存，意味着对EGFR酪氨酸激酶抑制剂（EGFR-TKIs）反应不佳。
Lung Cancer. 2016 Dec;102:101-107. doi: 10.1016/j.lungcan.2016.10.015. Epub 2016 Oct 31.
3
Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.在非小细胞肺癌中，BRCA1相关蛋白1（BAP1）表达缺失的情况较为罕见。
Hum Pathol. 2017 Feb;60:82-85. doi: 10.1016/j.humpath.2016.10.005. Epub 2016 Oct 28.
4
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.作为恶性胸膜间皮瘤中CDKN2A（p16）荧光原位杂交的补充，BAP1免疫组化的预后效用有限。
Hum Pathol. 2017 Feb;60:86-94. doi: 10.1016/j.humpath.2016.09.026. Epub 2016 Oct 19.
5
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.BAP1免疫组化和p16荧光原位杂交结果联合使用可提高恶性胸膜间皮瘤诊断的可信度：两种检测方法的ROC分析
Pathol Int. 2016 Oct;66(10):563-570. doi: 10.1111/pin.12453. Epub 2016 Sep 11.
6
BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.BAP1免疫染色及CDKN2A（p16）荧光原位杂交分析：在胸腔积液中诊断恶性间皮瘤的临床应用
Diagn Cytopathol. 2016 Jul;44(7):599-606. doi: 10.1002/dc.23491. Epub 2016 Apr 28.
7
Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.在非小细胞肺癌中，BAP1表达缺失非常罕见。
Pathology. 2016 Jun;48(4):336-40. doi: 10.1016/j.pathol.2016.03.005. Epub 2016 Apr 21.
8
[BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].[50例患者胸膜弥漫性恶性间皮瘤中BRCA1相关蛋白1（BAP1）的表达：细胞学与组织学对比分析]
Ann Pathol. 2016 Apr;36(2):111-9. doi: 10.1016/j.annpat.2016.01.005. Epub 2016 Mar 16.
9
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.BAP1免疫组化和p16荧光原位杂交技术在肉瘤样和促纤维增生性间皮瘤诊断中的应用
Am J Surg Pathol. 2016 May;40(5):714-8. doi: 10.1097/PAS.0000000000000616.
10
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.2015 年世界卫生组织胸膜肿瘤分类：相较于 2004 年分类的进展。
J Thorac Oncol. 2016 Feb;11(2):142-54. doi: 10.1016/j.jtho.2015.11.005.
Zotero 插件